Why is Hims & Hers Health stock down 4.8% today?

Traders Union
All News
Stocks
Hims & hers health slides 4.82% today

Highlights

Hims & Hers Health is scheduled to announce third quarter 2026 results on November 9 with revenue expected at $892.88 million and earnings per share of $0.06.
Multiple securities class action lawsuits are pending against the company, with a November 2 investor filing deadline approaching.
Shares of Hims & Hers Health trade down 4.82% at $25.37, under pressure from sellers, with a projected 5-day range of $23.66 to $27.22 and technical indicators showing bearish momentum.

Lawsuit deadlines and earnings forecast sustain bearish sentiment

Hims & Hers Health’s third quarter 2026 earnings are set for release on November 9, 2026, with market expectations of $892.88 million in revenue and $0.06 earnings per share. The company faces multiple securities class action lawsuits, with an investor filing deadline of November 2, 2026. These developments have kept Hims & Hers Health in focus, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees HIMS under persistent technical and sentiment pressure. He notes the stock’s failure to recover above key moving averages, signaling weak buyer conviction. The securities lawsuits and looming earnings add headline risk. Momentum indicators confirm sellers remain dominant, while volatility stays elevated. "Without a sharp reversal or a legal breakthrough, I see downside risk prevailing in the near term — traders must remain cautious here."

Viktoras Karapetjanc, expert at Traders Union, focuses on the upcoming earnings and long-term market potential. He highlights resilient revenue expectations and believes market attention will shift if the company delivers positive surprises. The class action risk is already reflected in sentiment, potentially setting up for a relief rally. "With Q3 results on the horizon, I expect the bullish structure to reemerge soon — this market offers constructive setups for forward-looking investors."

Sholanke Dele, market strategist, views the mood around HIMS as deeply negative. He observes that recent headlines have kept confidence low and inflows muted. Persistent legal risk weighs further on market psychology. "Until news flow turns decisively positive, I would avoid chasing rebounds — sentiment is simply too fragile right now."

Bearish momentum persists as all moving averages remain breached

Hims & Hers Health trades below its 20-day, 50-day, and 200-day moving averages ($28.38, $28.66, and $26.95), indicating sustained short-, medium-, and long-term pressure from sellers. The nearest resistance is at $26.28, while the closest support is the recent week low at $25.19, with all major trend-confirmation levels above the current price. Momentum indicators show a bearish setup: the MACD and ADX reveal weak bullish momentum and lack of trend strength. Oscillators including RSI, Stochastic RSI, and CCI remain neutral, not signaling overbought or oversold conditions. The Awesome Oscillator highlights continued seller dominance, and Bull/Bear Power suggests buyers still have some residual control. Intraday volatility remains elevated at 8.87%, and the stock holds near its session lows after a downside gap, confirming the overall negative tone.

Earlier, analysts noted that Hims & Hers Health faced persistent technical and legal headwinds that limited its rebound potential ahead of earnings. The current outlook reinforces this view, highlighting sustained downside risk and identifying $23.66 as the critical support level to monitor in the coming sessions.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.